COVID-19 Therapeutics Strategy: Commission identifies five promising candidate therapeutics

(Credit: Unsplash)

This article is brought to you in association with the European Commission.


The EU Strategy on COVID-19 Therapeutics delivers today its first outcome, with the announcement of the first portfolio of five therapeutics that could soon be available to treat patients across the EU. Four of these therapeutics are monoclonal antibodies under rolling review by the European Medicines Agency. Another one is an immunosuppressant, which has a marketing authorisation that could be extended to include the treatment of COVID-19 patients.

Commissioner for Health and Food Safety, Stella Kyriakides, said:“Today we are taking the first step towards a broad portfolio of therapeutics to treat COVID-19. Whilst vaccination is progressing at increasing speed, the virus will not disappear and patients will need safe and effective treatments to reduce the burden of COVID-19. Our goal is clear, we aim to identify more front-runner candidates under development and authorise at least three new therapeutics by the end of the year. This is the European Health Union in action.”

The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under the Strategy, provided the final data demonstrate their safety, quality and efficacy. The products are:

A new COVID-19 indication for existing medicines:

  • baricitinib immunosuppresant (a medicine that reduces the activity of the immune system) from Eli Lilly: an application for extension of marketing authorisation for COVID-19 indication is under assessment

Newly developed monoclonal antibodies under rolling review – a regulatory tool to speed up the assessment of a promising medicine during a public health emergency:

  • combination of bamlanivimab and etesevimab from Eli Lilly: under rolling review
  • combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: under rolling review
  • regdanivimab from Celltrion: under rolling review
  • sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.: under rolling review

Next Steps

The Commission will draw up a portfolio of at least 10 potential COVID-19 therapeutics by October, building on the work of the newly established expert group on COVID-19 variants.  The selection process will be objective and science based, with selection criteria agreed with the Member States. Since different types of products are needed for different patient populations and different stages and severity of the disease, the expert group will identify product categories and select the most promising therapeutics candidates for each category based on science based criteria. 

The portfolio will contribute to the objective of having at least three new therapeutics authorised by October and possibly two more by the end of the year. The European Medicines Agency will start more rolling reviews of promising therapeutics by end-2021, subject to research and development outcomes.

The Commission recently concluded a joint procurement of monoclonal antibodies (casirivimab and imdevimab) and could launch more by the end of the year.

The first industry matchmaking event on therapeutics will be organised on the 12-13 July to ensure that once authorised therapeutics are produced in sufficient quantity as soon as possible.

Background

The EU Strategy on COVID-19 Therapeutics aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use.

The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe’s health systems.

The Strategy, which focuses on the treatment of patients with COVID-19, works alongside the successful EU Vaccines Strategy, through which safe and effective vaccines against COVID-19 have been authorised for use in the EU to prevent and reduce transmission of cases, as well as hospitalisation rates and deaths caused by the disease.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

EU and China to do more in common if the global scene gets worse

Click and Download: your app is ready to help you save lives

WHO reports ‘very strong progress’ in battling DR Congo Ebola outbreak

New Eurobarometer survey shows: The majority of Europeans think the EU should propose additional measures to address air quality problems

Public Health equality in a trench

10 ways cities are tackling the global affordable housing crisis

Germany tries to save Europe from war between Ukraine and Russia

Long-term EU budget: It is not possible to do more with less, say MEPs

UN chief saddened at news of death of former US President George H.W. Bush

End discrimination against women and children affected by leprosy

Drought in southern Africa: EU releases over €22 million in humanitarian aid

These tech start-ups are changing what it means to farm

Attack on Saudi facilities risks dragging Yemen into ‘regional conflagration’: UN Envoy

Celebrating the Customs Union: the world’s largest trading bloc turns 50

How to outsmart bias when you’re recruiting

Primary Healthcare vs Specialization Careers, how to promote PHC to the Young Health Workforce?

Haitian Foreign Minister calls for development reboot to close ‘striking gap’ between promises and action on ending poverty

This is how drones and other ‘tradetech’ are transforming international trade

European Democracy Action Plan: making EU democracies stronger

Why we need a blockchain bill of rights

Prospect of a nuclear war ‘higher than it has been in generations’, warns UN

Antitrust: Commission imposes binding obligations on Gazprom to enable free flow of gas at competitive prices in Central and Eastern European gas markets

How 3 MENA business leaders are building resilient companies post-COVID-19

Thousands of health professionals call on world leaders to prioritize a greener future, post-pandemic

Kenya wants to run entirely on green energy by 2020

COVID vaccination campaign. What are the challenges?

Greece bailout ends but with no substantial effect on citizens’ life

1 million citizens try to create a new EU institution

What the next 20 years will mean for jobs – and how to prepare

Statement by Frans Timmermans, Executive Vice-President for the European Green Deal, on the announcement to postpone the COP26

EU and US take decisive step to end aircraft dispute

How COVID-19 is making companies act for the long term

We need tech solutions that value human interaction more than ever

Grievous violations continue against Myanmar civilians, Human Rights Council hears

The West and Russia accomplished the dismembering and the economic destruction of Ukraine

Guterres lauds UN peacekeeping, highlights need to bridge ‘critical’ gaps

How cities are failing to be inclusive – and what they can do about it

We must stop turning a blind eye to the world’s health crises

London wants to treat violent crime like a disease

Cybersecurity Act: build trust in digital technologies

MasterCard @ MWC14: Innovation in times of regulatory uncertainty

The digital revolution will transform the steel industry

‘Protracted crisis’ in Venezuela leads to ‘alarming escalation of tensions’: UN political chief

From battlefields to boardrooms: 3 steps to building high-morale teams

‘Act now with ambition and urgency’ to tackle the world’s ‘grave climate emergency’, UN chief urges UAE meeting

African cooperation on peace ‘increasingly strong’, Security Council told

European Green Deal: Commission presents actions to boost organic production

State aid: Commission approves €790 million Croatian guarantee scheme for companies with export activities affected by coronavirus outbreak

How COVID-19 might help us win the fight against climate change

Civilians suffering due to sanctions must be spared ‘collective punishment’ urges UN rights expert

5 urgent actions in the fightback against ransomware

The UN came of age with the nuclear bomb. Time for it to step up to the AI era

How can we prepare students for the Fourth Industrial Revolution? 5 lessons from innovative schools around the world

How digital identity can improve lives in a post-COVID-19 world

How we measure stakeholder capitalism will determine our recovery

Commission disburses €14.1 billion under SURE to 12 Member States

How distorted is the EU labour market by this crisis?

UN study projects $32 billion loss for UK post no-deal Brexit

One for all? Are physicians prepared to deliver care to the LGBTQIA+ community?

Trade surplus up production down in Eurozone

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s